Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1h-pyrrolizine-7a(5h)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, Hydrochloride (1:1)
2. 1h-pyrrolizine-7a(5h)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, Hydrochloride Hemihydrate
3. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide Hydrochloride
4. Pilsicainide
5. Pilsicainide Hydrochloride Hemihydrate
6. Pilsicainide Hydrochloride Hydrate
7. Sun 1165
8. Sun-1165
9. Tetrahydro-1h-pyrrolizine-7a(5h)-aceto-2',6'-xylidide
1. 88069-49-2
2. Pilsicainide Hcl
3. N-(2,6-dimethylphenyl)-2-(hexahydro-1h-pyrrolizin-7a-yl)acetamide Hydrochloride
4. Sunrythm
5. Pilsicainide (hydrochloride)
6. Sun 1165
7. Pilsicainide Hydrochoride
8. Sun 1165; Sunrythm
9. 88069-49-2 (hcl)
10. 03c8i9296v
11. Sun-1165
12. N-(2,6-dimethylphenyl)-2-(tetrahydro-1h-pyrrolizin-7a(5h)-yl)acetamide Hydrochloride
13. N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide;hydrochloride
14. Unii-03c8i9296v
15. Pilsicainide Hydrochloride [jan]
16. N-(2,6-dimethylphenyl)-1h-pyrrolizine-8-acetamide Hydrochloride
17. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide Monohydrochloride
18. 1h-pyrrolizine-8-acetamide, Hexahydro-n-(2,6-dimethylphenyl)-, Hydrochloride
19. N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide Hydrochloride
20. Schembl483632
21. Chembl4303511
22. Dtxsid7057860
23. Amy8863
24. Bcp09636
25. Mfcd00903769
26. Akos025287418
27. Ds-9555
28. Du-6552
29. 1h-pyrrolizine-7a(5h)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, Monohydrochloride
30. Pilsicainide Hydrochloride [who-dd]
31. Hy-101245
32. Pilsicainide Hydrochloride, >=98% (hplc)
33. Cs-0021031
34. Ft-0630955
35. P2634
36. 69p492
37. A16362
38. C76901
39. A842458
40. Q27247552
41. 1h-pyrrolizine-7a(5h)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, Hydrochloride (1:1)
42. N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide,hydrochloride
43. N-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)ethanamide Hydrochloride
44. N-(2,6-dimethylphenyl)-2-(hexahydro-1h-pyrrolizin-7a-yl)acetamide Hcl
45. N-(2,6-dimethylphenyl)-2-(hexahydro-1h-pyrrolizin-7a-yl)acetamidehydrochloride
Molecular Weight | 308.8 g/mol |
---|---|
Molecular Formula | C17H25ClN2O |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 308.1655411 g/mol |
Monoisotopic Mass | 308.1655411 g/mol |
Topological Polar Surface Area | 32.3 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 348 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Sodium Channel Blockers
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity. (See all compounds classified as Sodium Channel Blockers.)
ABOUT THIS PAGE
A Pilsicainide Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pilsicainide Hydrochloride, including repackagers and relabelers. The FDA regulates Pilsicainide Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pilsicainide Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pilsicainide Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pilsicainide Hydrochloride supplier is an individual or a company that provides Pilsicainide Hydrochloride active pharmaceutical ingredient (API) or Pilsicainide Hydrochloride finished formulations upon request. The Pilsicainide Hydrochloride suppliers may include Pilsicainide Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Pilsicainide Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pilsicainide Hydrochloride Drug Master File in Japan (Pilsicainide Hydrochloride JDMF) empowers Pilsicainide Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pilsicainide Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Pilsicainide Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pilsicainide Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pilsicainide Hydrochloride Drug Master File in Korea (Pilsicainide Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pilsicainide Hydrochloride. The MFDS reviews the Pilsicainide Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Pilsicainide Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pilsicainide Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pilsicainide Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pilsicainide Hydrochloride suppliers with KDMF on PharmaCompass.
Pilsicainide Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pilsicainide Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pilsicainide Hydrochloride GMP manufacturer or Pilsicainide Hydrochloride GMP API supplier for your needs.
A Pilsicainide Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Pilsicainide Hydrochloride's compliance with Pilsicainide Hydrochloride specifications and serves as a tool for batch-level quality control.
Pilsicainide Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Pilsicainide Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pilsicainide Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Pilsicainide Hydrochloride EP), Pilsicainide Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pilsicainide Hydrochloride USP).
LOOKING FOR A SUPPLIER?